Table 2 Immunomodulatory therapy
PatientPrevious IMTConcomitant medicationTime to control inflammation (weeks)Adverse effectsTreatment status
1MM, MTX, INFMM, MTX, CLX, PF2NoneOngoing
2MTX, ETPMTX, PF3.3NoneOngoing
3MM, MTX, CSA, ETPMM4.3NoneOngoing
4MTX, CSACSA, PF1.7NoneOngoing
5MTX, ETPMTX, MM, PF8.6NoneOngoing
6MM, CSAPF, BFC4.7Elevated LFT*Ongoing
7MTXMM, PF3.7NauseaDiscontinued
8NoneMTX, PF20Elevated LFT*Ongoing
9MTXMM, PF45NoneOngoing
10MTXMM2NoneOngoing
11MMMTX, PRED, PF, BFC5.9NoneOngoing
12NoneMTX, PF7NoneRemission
13MTXMM, LE7.3NoneOngoing
14CSA, MMPF4.3NoneOngoing
15MTX, MMMTX, MM, PF9.7NoneOngoing
16MM, ETPMM, PF4.3Leukopenia*Ongoing
17MTX, CHLMTX, MEL5.3NoneOngoing
18MTX, ETPMM, CSA, PF, ATO12.3NoneOngoing
19MTX, CSA, AZARIM25Leukopenia*Remission
20MTX, CSA, MM, CHLPF, IV MPD46.3Fatigue, myalgiaRemission
21MM, CSA, SIRMM, CSA, SIR, PF6.4NauseaOngoing
22MTX, MMMM, PRED, PF, BFC8Leukopenia*Ongoing
23MTX, MM, CSANone3.4Leukopenia*Ongoing
  • ATO, Atropine 1% drops; AZA, azathioprine; BFC, bromfenac 0.09%; CHL, chlorambucil; CLX, celecoxib; CSA, cyclosporine; ETP, etanercept; INF, infliximab; IV MPD, intravenous methylprednosolone; LE, loteprednol etabonate 0.5% drops; LFT, liver function test; MEL, meloxicam; MM, mycophenolate mofetil; MTX, methotrexate; PF, prednisolone 1%; PRED, oral prednisone; RIM, rimexolone 1%, SIR, sirolimus. *Transient.